Core Viewpoint - The logic of multinational pharmaceutical companies "shopping" in the Chinese market is undergoing a subtle differentiation, with some companies focusing on early-stage asset incubation and technology licensing, while others are shifting their attention to collaborations in the later stages of drug pipeline development and commercialization [3][6]. Group 1: Market Dynamics - The first innovative drug for post-operative precision assessment of differentiated thyroid cancer, injection human thyroid-stimulating hormone β (Zesuning®), was prescribed in March at two hospitals in China [3]. - Differentiated thyroid cancer has seen a rapid increase in incidence in China, with over 90% of cases being differentiated thyroid cancer, and a 10-year recurrence rate of 19% post-surgery [3][4]. - The collaboration between Zai Lab and Merck for Zesuning® involved a payment of 250 million yuan for exclusive promotion rights in mainland China [4]. Group 2: Collaboration Trends - Merck's strategy focuses on partnering with projects that are in the later stages of development, indicating a shift towards more cautious and controlled risk in drug licensing agreements [5][6]. - The number and scale of innovative drug licensing transactions initiated by multinational pharmaceutical companies have been increasing, with projections indicating that by 2025, the total value of these transactions in China will exceed $130 billion [6]. Group 3: Challenges and Opportunities - Despite the growth in licensing transactions, there is a notable "return rate" of 40% for collaborations initiated in 2020, highlighting challenges in clinical data expectations and strategic shifts [6]. - Zai Lab's collaboration with Merck is focused on the domestic market, aiming to address unmet clinical needs in China, where over 500,000 new thyroid cancer patients are diagnosed annually [7]. - The need for partnerships arises from the limited commercialization capabilities of many small and medium-sized biotech companies in China, which necessitates collaboration with firms that have established commercial networks [7][8].

Core Viewpoint - Zejing Pharmaceutical has entered into a global development and commercialization strategic cooperation and licensing option agreement with AbbVie for ZG006, which includes significant upfront and milestone payments, indicating strong potential for revenue growth and market expansion in oncology treatments [1][3]. Group 1: ZG006 Collaboration with AbbVie - The agreement grants AbbVie exclusive rights to develop and commercialize ZG006 outside Greater China, while Zejing retains rights within the region [3]. - Zejing has received an upfront payment of $100 million and may receive up to $60 million in milestone payments, with potential additional milestone payments of up to $1.075 billion if the licensing option is exercised [3]. - The collaboration is expected to enhance Zejing's innovation profile and international influence, providing more treatment options for global patients [3]. Group 2: Clinical Data and Progress of ZG006 - ZG006 is currently in clinical trials for small cell lung cancer and neuroendocrine cancer, showing promising efficacy and safety [4]. - In a Phase II trial for late-stage small cell lung cancer, ZG006 demonstrated an overall response rate (ORR) of 53.3% and a median progression-free survival (mPFS) of 7.03 months [4]. - In neuroendocrine cancer patients, the ORR was 38.5%, with a notable 66.7% in DLL3-positive patients [4]. Group 3: ZG005 Clinical Data and Development - ZG005 is advancing in clinical trials for liver cancer, neuroendocrine cancer, and cervical cancer, with a confirmed ORR of 40.9% and disease control rate (DCR) of 68.2% in cervical cancer patients [5]. - The drug has shown encouraging activity in early studies for advanced cervical cancer and liver cancer, indicating broad potential for combination therapies [5]. Group 4: Sales and Market Strategies - The injection of human thyroid-stimulating hormone β (Zesuning®) has been approved for post-surgical diagnosis in differentiated thyroid cancer, marking it as the first innovative product in this area in China [6]. - Zejing has partnered with Merck for exclusive promotion of Zesuning®, aiming to enhance its market presence in personalized diagnosis for thyroid cancer patients [6]. - The company’s Jikaxitini tablets have been included in the national medical insurance directory, expected to positively impact sales due to its classification as a first-line treatment in clinical guidelines [7]. Group 5: Financial Performance Forecast for 2025 - Zejing anticipates revenue between 796.49 million and 828.99 million yuan for 2025, representing a year-on-year increase of 49.45% to 55.55% [9]. - The revenue growth is primarily driven by the inclusion of recombinant thrombin in the national medical insurance directory and the commercialization of Jikaxitini [9]. - Despite the revenue increase, the company expects to report a net loss due to rising sales and research expenses [9].

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, with a focus on AI-enabled strategic upgrades in pharmaceutical manufacturing [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a 5.6% increase from December 29, 2025, to January 9, 2026, outperforming the Wind All A index (4.76%) and the CSI 300 index (2.18%). Key segments leading this growth include hospitals (12.95%), medical research outsourcing (9.25%), and medical devices (7.96%) [2][7]. - The report highlights the rapid development of AI in healthcare, emphasizing the government's initiative to foster AI in drug development, supply chain management, surgical robotics, and intelligent diagnostic systems by 2027. This initiative aims to cultivate 2-3 leading ecological enterprises and a number of specialized companies [2][11]. - The upcoming JPM Healthcare Conference from January 12 to 15, 2026, is expected to boost the sentiment in the innovative drug sector, with over 500 listed companies and thousands of startups participating [2][11]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 5.6% during the last interval, with hospitals, medical research outsourcing, and medical devices leading the gains. Notably, the stock of Sanbo Brain Science surged by 63.53%, while *ST Changyao saw a decline of 44.9% [7][10]. - The report provides detailed performance metrics for various sub-sectors, with hospitals showing a 12.95% increase, medical research outsourcing at 9.25%, and medical devices at 7.96% [8][9]. Industry News and Key Company Announcements - On January 7, eight departments jointly issued the "AI + Manufacturing" action plan, marking AI drug development and medical supply chain intelligence as national priorities [11]. - Notable company announcements include: - Yilian Bio's exclusive licensing agreement with Roche for the YL201 project, which includes a $570 million upfront payment [11]. - Merck's discussions to acquire Revolution Medicines for $28 billion to $32 billion [11]. - Structure Therapeutics' agreement with Roche and Genentech for a non-exclusive patent license, resulting in a $100 million upfront payment [11][12]. - Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion [14].